Full Breakdown
Supplemental PALISADE Data Sparks Abivax Stock Surge
7/1/2026, 2:41:34 AM
New PALISADE Maintenance Data Revives Obefazimod Prospects
On June 30, 2026, Abivax released supplemental results from the Phase 3 PALISADE maintenance study of obefazimod in ulcerative colitis. The data, covering 1,704 patient-years, showed malignancy rates of 0.35 events per 100 patient-years, within the 0.30-0.70 expected range. Clinical remission was achieved by 37.2 % of induction non-responders on 50 mg and by 45.5 % of patients who escalated from 25 mg to 50 mg after relapse. The announcement triggered a 35-40 % surge in Paris-listed shares and a 29 % jump in U.S. ADS after hours.
Earlier Safety Concerns and Market Reaction
In early June, a preliminary readout identified seven cancer diagnoses among trial participants, prompting a 44 % drop in Abivax’s stock and speculation about a boxed warning. Remission rates of 50.8 % (25 mg) and 51.3 % (50 mg) versus 10.4 % placebo were already noted, but the cancer signal dominated investor sentiment.
Key Efficacy and Safety Metrics
The trial encompassed 1,704 patient-years of exposure. Malignancies (excluding non-melanoma skin cancer) occurred at 0.35/100 patient-years (range 0.30-0.70); non-melanoma skin cancer at 0.59/100 patient-years (range 0.70-1.40). Clinical remission was 37.2 % (induction non-responders, 50 mg) and 45.5 % (relapsers after dose escalation); endoscopic remission reached 34.5 % (induction non-responders, 50 mg). Overall remission at week 44 was 50.8 % (25 mg) and 51.3 % (50 mg) versus 10.4 % placebo.
Official Company Statements
Abivax said the safety dataset “strengthens our confidence” in obefazimod’s long-term outlook and confirmed its intent to file a U.S. NDA in Q4 2026. The firm reported €491.6 million in cash and investments, enough to fund operations through Q4 2027. It also noted ongoing Phase 2b testing in Crohn’s disease, with topline results expected mid-2027.
Analyst Criticism and Market Skepticism
Jefferies analysts warned that cancer risk remains a concern and highlighted a sparse catalyst path, cash needs, and uncertain acquisition prospects. Oddo BHF said the data do not prove a definitive absence of risk. Concerns persist about labeling implications and the company’s cash runway.
Conflicting Reports & Remaining Gaps
The June 1 interim analysis reported seven cancer diagnoses, prompting a sharp share decline. The June 30 supplemental data place malignancy incidence within expected background rates, but no definitive evidence has ruled out a causal link, and regulators have not confirmed the labeling outcome. Long-term safety beyond the 44-week maintenance period remains untested.
Verbatim Quotes
- “substantially expanding our long-term safety database.” — Marc de Garidel, CEO, Abivax
- “consistent with expected background rates.” — Remo Panaccione, Professor, University of Calgary
- “cancer risk may be tough to discount, sparse catalyst path, cash needs, catalyst path ex-M&A.” — Jefferies analyst
Outlook: Regulatory Filing and Future Trials
Abivax aims to submit its U.S. NDA for obefazimod in ulcerative colitis by Q4 2026, followed by a half-year report on September 21. A Phase 2b Crohn’s disease trial is ongoing, with topline data expected mid-2027. Investors will watch the FDA’s labeling decision and the company’s ability to sustain its cash position while advancing the pipeline.
